+40 21 323 6868
+40 21 323 6868
GLC monitoring mission report 2016

GLC monitoring mission report 2016

Overview

The rGLC/Europe supports the implementation and expansion of the M/XDR-TB Response Plan in Romania. Since the launch of the GFATM project, rGLC has conducted annual monitoring missions, with the latest occurring in March 2015.

Key approvals and patient inclusions

Romania received several approvals from GLC for access to quality-assured second-line drugs for a total of 850 MDR-TB patients. Between 2004-2011, a total of 884 MDR-TB patients were included in GLC-approved programs, funded by GFATM grants.

Treatment success rates

  • First three cohorts (2004-2005, 2006-2007, 2009): 364 MDR-TB patients, with an average treatment success rate of 66.8%
  • 2011 cohort: treatment success rate of 73.6%

Despite the good performance of GFATM grants related to the TB Program in Romania, the treatment efficacy for non-GLC patient cohorts showed extremely poor results over the years due to various structural, financial, and organizational constraints.

Recent developments

  • Early 2013: GFATM approved TFM funding for a new cohort of 300 patients to be included in 2013-2014. This program started in October 2013 and included treatment regimens for 19 XDR-TB patients.
  • Future Projections: An additional 1,460 M/XDR-TB patients will have access to quality-assured second-line drugs and new Group 5 medications, with funding available from the Norwegian Fund and GFATM until March 2018.

For more information, you can download the document below.

GLC-EUROPE MONITORING MISSION